IOVA - Iovance Biotherapeutics Inc Stock Price, Fair Value and News

12.05USD+0.27 (+2.29%)Delayed as of 01 May 2024, 02:04 pm ET

Market Summary

USD12.05+0.27

Delayedas of 01 May 2024, 02:04 pm

2.29%

IOVA Stock Price

View Fullscreen

IOVA RSI Chart

IOVA Valuation

Market Cap

3.3B

Price/Earnings (Trailing)

-7.41

Price/Sales (Trailing)

2.8K

EV/EBITDA

-7.32

Price/Free Cashflow

-8.57

IOVA Price/Sales (Trailing)

IOVA Profitability

Operating Margin

-804.54%

EBT Margin

-37465.52%

Return on Equity

-75.95%

Return on Assets

-56.9%

Free Cashflow Yield

-11.67%

IOVA Fundamentals

IOVA Revenue

Revenue (TTM)

1.2M

IOVA Earnings

Earnings (TTM)

-444.0M

Earnings Growth (Yr)

-10.5%

Earnings Growth (Qtr)

-2.3%

Breaking Down IOVA Revenue

52 Week Range

4.0112.10

(Low)(High)

Last 7 days

-0.7%

Last 30 days

-20.5%

Last 90 days

52.4%

Trailing 12 Months

83.2%

How does IOVA drawdown profile look like?

IOVA Financial Health

Current Ratio

2.79

IOVA Investor Care

Shares Dilution (1Y)

24.56%

Diluted EPS (TTM)

-1.89

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Iovance Biotherapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	bilinsky igor	acquired	-	-	2,812	chief operating officer
Apr 15, 2024	graf finckenstein friedrich	acquired	-	-	2,812	chief medical officer
Apr 15, 2024	graf finckenstein friedrich	sold (taxes)	-16,967	11.89	-1,427	chief medical officer
Apr 15, 2024	vogt frederick g	sold (taxes)	-105,238	11.89	-8,851	interim ceo & general counsel
Apr 15, 2024	vogt frederick g	acquired	-	-	20,834	interim ceo & general counsel
Apr 15, 2024	bilinsky igor	sold (taxes)	-16,967	11.89	-1,427	chief operating officer
Mar 04, 2024	bilinsky igor	sold (taxes)	-123,588	16.96	-7,287	chief operating officer
Mar 04, 2024	vogt frederick g	acquired	-	-	41,662	interim ceo & general counsel
Mar 04, 2024	vogt frederick g	sold (taxes)	-194,175	16.96	-11,449	interim ceo & general counsel
Mar 04, 2024	graf finckenstein friedrich	sold (taxes)	-136,579	16.96	-8,053	chief medical officer

Which funds bought or sold IOVA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 29, 2024	China Universal Asset Management Co., Ltd.	added	81.43	555,000	796,000	0.10%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	new	-	152,000	152,000	-%
Apr 29, 2024	PRINCIPAL FINANCIAL GROUP INC	reduced	-23.91	8,294,180	29,727,500	0.02%
Apr 29, 2024	FIRST UNITED BANK & TRUST	new	-	14,820	14,820	-%
Apr 29, 2024	HAZLETT, BURT & WATSON, INC.	unchanged	-	-	1,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-1.88	5,451,040	12,363,200	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	added	33.09	511,820	870,719	-%
Apr 25, 2024	Lindbrook Capital, LLC	added	1.34	17,999	39,243	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	4,897	10,849	-%
Apr 25, 2024	SHAKER INVESTMENTS LLC/OH	new	-	1,172,070	1,172,070	0.50%

Are Funds Buying or Selling IOVA?

Are funds buying IOVA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IOVA

No. of Funds

Unveiling Iovance Biotherapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 19, 2024	quogue capital llc	11.6%	3e+07	SC 13D/A
Mar 01, 2024	perceptive advisors llc	6.9%	19,221,743	SC 13G
Feb 14, 2024	point72 asset management, l.p.	0%	0	SC 13G/A
Feb 14, 2024	perceptive advisors llc	4.7%	11,979,415	SC 13G/A
Feb 13, 2024	vanguard group inc	8.91%	22,812,820	SC 13G/A
Feb 09, 2024	mhr fund management llc	6.9%	17,605,902	SC 13G/A
Jan 26, 2024	blackrock inc.	7.5%	19,071,756	SC 13G/A
Jan 25, 2024	state street corp	6.42%	16,424,388	SC 13G/A
Oct 27, 2023	quogue capital llc	15.84%	2.5e+07	SC 13D/A
Feb 17, 2023	point72 asset management, l.p.	4.6%	7,347,600	SC 13G

Recent SEC filings of Iovance Biotherapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 03, 2024	8-K	Current Report
Mar 29, 2024	8-K	Current Report
Mar 19, 2024	SC 13D/A	13D - Major Acquisition
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading

Peers (Alternatives to Iovance Biotherapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.1B	6.8B	3.52%	-17.31%	-8.94	6.15	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-3.68%	-28.69%	-41.18	9.92	76.23%	61.08%
BMRN	15.3B	2.5B	-7.53%	-16.73%	74.64	6.2	13.74%	186.89%
INCY	11.7B	3.8B	-8.64%	-30.91%	15.68	3.1	8.58%	129.81%
MID-CAP
APLS	5.3B	396.6M	-24.84%	-46.72%	-10.08	13.44	425.83%	18.94%
BBIO	4.5B	-	-17.14%	78.66%	-6.9	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.57%	4.22%	-14.61	12.91	440.80%	-27.84%
ARWR	2.8B	240.7M	-20.91%	-36.67%	-9.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-9.63%	-23.17%	-44.93	3.79	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-5.58%	-11.16%	24.84	4.45	85.90%	-14.05%
NVAX	606.0M	983.7M	-9.41%	-43.91%	-1.11	0.62	-50.36%	17.16%
CRBP	388.7M	881.7K	-5.61%	336.79%	-8.71	466.16	-77.61%	-5.33%
INO	267.6M	4.9M	-17.51%	25.55%	-1.98	54.99	-54.97%	51.71%
IBIO	6.0M	2.1M	-57.88%	56.88%	-0.22	2.14	-13.45%	66.37%

Iovance Biotherapeutics Inc News

Latest updates

Iovance Biotherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2
Revenue	-100.0%	-	469,000	238,000
Cost Of Revenue	-100.0%	-	4,340,000	2,050,000
Costs and Expenses	2.4%	121,738,000	118,830,000	110,324,000
S&GA Expenses	10.9%	29,903,000	26,964,000	21,927,000
R&D Expenses	-0.1%	87,470,000	87,526,000	86,347,000
EBITDA Margin	-Infinity%	-364	-	-
Income Taxes	-41.5%	-1,759,000	-1,243,000	-500,000
Earnings Before Taxes	-2.7%	-118,138,000	-115,003,000	-107,005,000
EBT Margin	-Infinity%	-374	-	-
Net Income	-2.3%	-116,379,000	-113,760,000	-106,528,000
Net Income Margin	-Infinity%	-373	-	-
Free Cashflow	0.2%	-87,499,000	-87,660,000	-103,520,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-8.4%	780	852	757	825	664	546	611	701	777	829	853	751	768	782	818	288	345	396	436	462	481
Current Assets	-19.5%	308	383	275	638	479	370	432	490	508	583	667	605	636	724	783	256	316	367	411	445	475
Cash Equivalents	-57.1%	115	268	230	543	232	118	108	92.00	78.00	59.00	83.00	132	73.00	68.00	161	53.00	19.00	39.00	77.00	54.00	82.00
Inventory	12.8%	10.00	9.00	10.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	0.8%	114	113	113	110	105	101	101	103	101	88.00	80.00	73.00	59.00	39.00	19.00	14.00	9.00	6.00	4.00	4.00	3.00
Liabilities	9.8%	196	178	179	158	164	152	138	149	156	130	108	103	112	70.00	59.00	45.00	46.00	41.00	39.00	27.00	15.00
Current Liabilities	21.3%	110	91.00	89.00	87.00	91.00	79.00	64.00	77.00	89.00	65.00	61.00	55.00	55.00	64.00	55.00	40.00	39.00	35.00	34.00	22.00	14.00
Shareholder's Equity	-13.3%	585	674	579	667	500	394	473	552	622	698	744	647	656	712	758	243	299	355	397	435	466
Retained Earnings	-6.1%	-2,012	-1,896	-1,782	-1,675	-1,568	-1,463	-1,363	-1,264	-1,172	-1,073	-986	-905	-830	-761	-703	-640	-570	-507	-457	-410	0.00
Additional Paid-In Capital	0.6%	2,594	2,579	2,360	2,343	2,069	1,859	1,839	1,818	1,795	1,771	1,731	1,553	1,487	1,473	1,461	883	869	0.00	0.00	845	839
Shares Outstanding	0.1%	256	256	225	224	188	158	157	157	157	156	151	149	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,400	-	-	-	1,600	-	-	-	3,800	-	-	-	3,700	-	-	-	2,900	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	0.1%	-83,970	-84,083	-93,967	-99,800	-77,671	-63,649	-77,635	-73,802	-53,849	-57,693	-54,008	-62,391	-62,692	-40,515	-36,635	-65,292	-53,822	-42,182	-33,795	-29,090	-31,549
Share Based Compensation	-9.0%	14,399	15,821	16,740	15,665	19,509	19,780	22,468	22,265	19,104	19,306	14,414	16,941	10,232	10,706	10,537	9,412	5,407	6,598	6,426	5,846	5,254
Cashflow From Investing	7.8%	-72,845	-79,014	-156,779	153,396	461	73,715	95,763	86,516	69,338	12,748	-159,165	77,211	58,753	-52,955	-423,756	100,105	26,814	3,495	58,683	1,033	-206,382
Cashflow From Financing	-99.5%	962	202,800	1,025	258,172	190,575	225	-2,067	1,417	4,150	20,772	163,982	50,364	2,958	1,166	568,465	3,833	2,088	664	3,381	-2.00	239,345

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IOVA Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Consolidated Statements of Operations
Total revenue	$ 1,189
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	us-gaap:ProductMember
Costs and expenses
Cost of sales	$ 10,755
Research and development	344,077	$ 294,781	$ 259,039
Selling, general and administrative	106,916	104,097	83,664
Total costs and expenses	461,748	398,878	342,703
Loss from operations	(460,559)	(398,878)	(342,703)
Other income
Interest income, net	13,043	2,985	451
Net Loss before income taxes	(447,516)	(395,893)	(342,252)
Income tax benefit	3,479	0	0
Net Loss	$ (444,037)	$ (395,893)	$ (342,252)
Net Loss Per Share of Common Stock, Basic	$ (1.89)	$ (2.49)	$ (2.23)
Net Loss Per Share of Common Stock, Diluted	$ (1.89)	$ (2.49)	$ (2.23)
Weighted Average Shares of Common Stock Outstanding, Basic	235,131	159,259	153,406
Weighted Average Shares of Common Stock Outstanding, Diluted	235,131	159,259	153,406

IOVA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 114,888	$ 231,731
Trade accounts receivable	151
Short-term investments	164,979	240,114
Inventory	10,372
Prepaid expenses and other assets	17,458	7,271
Total Current Assets	307,848	479,116
Property and equipment, net	114,030	105,232
Intangible assets, net	229,258
Operating lease right-of-use assets	62,515	73,015
Restricted cash	66,430	6,430
Long-term assets	270	189
Total Assets	780,351	663,982
Current Liabilities
Accounts payable	33,123	26,603
Accrued expenses	69,406	52,295
Operating lease liabilities	7,777	12,587
Total Current Liabilities	110,306	91,485
Non-Current Liabilities
Operating lease liabilities - non-current	67,085	71,859
Deferred tax liabilities	17,347
Long-term note payable	1,000	1,000
Total Non-Current Liabilities	85,432	72,859
Total Liabilities	195,738	164,344
Commitments and contingencies
Stockholders' Equity
Common stock, $0.000041666 par value; 500,000,000, and 300,000,000 shares authorized, 256,135,715 and 187,812,072 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	11	8
Accumulated other comprehensive income (loss)	2,526	(902)
Additional paid-in capital	2,594,448	2,068,867
Accumulated deficit	(2,012,375)	(1,568,338)
Total Stockholders' Equity	584,613	499,638
Total Liabilities and Stockholders' Equity	780,351	663,982
Series A Convertible Preferred Stock
Stockholders' Equity
Preferred stock, Value	0	0
Series B Convertible Preferred Stock
Stockholders' Equity
Preferred stock, Value	$ 3	$ 3

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'UniversitÃƒÂ© de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

CEO	Dr. Frederick G. Vogt Esq., J.D., Ph.D.
WEBSITE	iovance.com
INDUSTRY	Biotechnology
EMPLOYEES	503

Iovance Biotherapeutics Inc Frequently Asked Questions

What is the ticker symbol for Iovance Biotherapeutics Inc? What does IOVA stand for in stocks?

IOVA is the stock ticker symbol of Iovance Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Iovance Biotherapeutics Inc (IOVA)?

As of Tue Apr 30 2024, market cap of Iovance Biotherapeutics Inc is 3.29 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IOVA stock?

You can check IOVA's fair value in chart for subscribers.

What is the fair value of IOVA stock?

You can check IOVA's fair value in chart for subscribers. The fair value of Iovance Biotherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Iovance Biotherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IOVA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Iovance Biotherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether IOVA is over valued or under valued. Whether Iovance Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Iovance Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IOVA.

What is Iovance Biotherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, IOVA's PE ratio (Price to Earnings) is -7.41 and Price to Sales (PS) ratio is 2.77 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IOVA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Iovance Biotherapeutics Inc's stock?

In the past 10 years, Iovance Biotherapeutics Inc has provided 0.028 (multiply by 100 for percentage) rate of return.